1 In a placebo controlled double-blind study including 10 patients with heart failure the nisoldipine/digoxin interaction was studied. 2 Nisoldipine was shown to elevate digoxin plasma concentrations significantly by about 15% (trough levels). 3 During chronic combination therapy with nisoldipine trough levels and plasma concentrations 4 h after the morning dose of digoxin were 1.35 ± 0.14 and 1.92 ± 0.16 ng ml-' respectively, whereas they averaged to 1.16 ± 0.14 and 1.52 + 0.16 ng ml-1 with digoxin and placebo (P < 0.05; mean + s.e. mean). 4 Systolic time intervals were significantly altered by nisoldipine co-administration compared with digoxin plus placebo. 5 In certain patients the elevation of digoxin plasma levels due to nisoldipine coadministration could be of clinical relevance.
Introduction
Several reports about elevated bioavailability and an altered haemodynamic effect of digoxin during simultaneous ingestion of calcium channel blockers like nifedipine, verapamil and gallopamil have been published (Belz et al., 1983; Kirch et al., 1984 Kirch et al., , 1986a Pedersen et al., 1983) . In the case of nifedipine the results in the literature are controversial (Kuhlmann, 1985; Schwartz et al., 1984) . Digitoxin plasma levels do not appear to be influenced by concurrent administration of a calcium antagonist like for example nitrendipine (Kirch et al., 1984) . This might be due to the predominant hepatic excretion route of this digitalis glycoside (Kirch et al., 1986b) . Nisoldipine is a new dihydropyridine substance, which does not exert an electro-physiological effect on sinus and AV-node but has a marked peripheral vasodilating activity (Debbas et al., 1984; Hess & Krayenbuhl, 1984; Kazda et al., Correspondence: Priv.-Doz. Dr W. Kirch, Med. Klinik, 12, D-2300 Kiel, FRG 1980; Meredith etal., 1985; Pasanisi etal., 1985) . Therefore this calcium antagonist appears to be specifically indicated for patients with coronary disease, heart failure and/or arterial hypertension and it might be frequently given concurrently with digitalis glycosides.
The aim of the present study was to clear up a possible pharmacokinetic and haemodynamic interaction between nisoldipine and digoxin.
Methods
The study was started with 10 patients (seven female, three male) aged from 21 to 74 years (61.3 -+-5.1; mean + s.e. mean) with cardiac insufficiency, NYHA stage II-III. The data of nine patients were included in the statistical analysis of the study, as one patient failed to Christian-Albrechts Universitat, Schittenhelmstrasse complete the investigation (Table 1) . He did not come to the control dates from the placebo phase onwards. The patients, who were all on previous digoxin therapy for at least 3 months, had given their written informed consent to participate in the study. The protocol of the study was approved by a local hospital ethics committee. Estimation of their digitalis glycoside plasma concentrations on three different days before the study confirmed that their plasma levels were in the steady state range.
In a placebo controlled double-blind crossover study the patients were treated in a randomized order for 7 days, first with digoxin (Lanicorg, Boehringer Mannheim, FRG) 0.25 mg twice daily plus a tablet of placebo twice daily or digoxin 0.25 mg twice daily combined with nisoldipine 10 mg twice daily. Thereafter the crossover to the corresponding therapy period lasting again 7 days was performed. Patients were treated for at least 14 days prior to the study with digoxin 0.25 mg twice daily.
Plasma samples for determination of digoxin were collected during each treatment week on day 5, 6 and 7 before and 4 h after the morning dose. The plasma levels of digoxin were estimated by a commercially available radio-immunoassay (RIA; Diagnostic Products Corporation). Systolic time intervals (STI) were determined on day 7 of each treatment week before the morning dose, 3 and 8 h afterwards, whereby detailed restrictions concerning food, fluid and physical activities were strictly adhered. STJ were determined after an overnight fast (pre-dose and 3-h values). Thereafter a standardized breakfast with caffeine-free beverages was given. Drinking of alcoholic beverages and smoking were not allowed on day 7 of each treatment period. Also strenuous physical exercises were forbidden 12 h before the pre-dose values and on the entire day 7. Preceding the 8 h value besides the breakfast no other meal was taken by the patients. Systolic time intervals were calculated from simultaneous recordings of ECG, phonocardiogram and carotid pulse tracing in supine position after a 15 min resting period, using 3-channel Cardirex 3T recorder (Siemens). Measurements were made from five consecutive heart beats (Erbel & Belz, 1977 ) at a paper speed of 100 mm s-, they were repeated three times, and then the results were averaged. Total electromechanical systole (QS2) was measured from the beginning of the QRS complex in ECG to the beginning of the high frequency vibrations of the second heart sound in phonocardiogram. Left ventricular ejection time (LVET) was measured from the beginning of the upstroke to the dicrotic notch in the carotid pulse tracing. Pre-ejection period 1.39 ± 0.20 1.24 ± 0.27 1.33 ± 0.21* 1.35 ± 0.14** Digoxin + nisoldipine 4 h post-dosing 2.04 ± 0.27* 2.07 ± 0.27* 1.64 ± 0.27 1.92 ± 0.16** concentrations *P < 0.05, *P < 0.02 compared with monotherapy, ***average of all individual data taken together for days 5, 6, and 7 *P < 0.05 compared with digoxin monotherapy a significant shortening of pre-ejection period from 139 + 11 ms with placebo to 129 + 11 ms with nisoldipine co-administration was found (P < 0.05). Also the ratio PEP/LVETC was significantly decreased from 0.395 ± 0.037 to 0.356 ± 0.036 ms (P < 0.05; Table 3 ).
Adverse effects
One patient complained about slight headache and one patient about weakness, when nisoldipine was co-administered. With digoxin plus placebo another patient reported headache and one patient described reddening of the face on the seventh treatment day.
Discussion
Comparable to results found for other calcium channel blockers like verapamil, gallopamil, nifedipine and nitrendipine, in the present study the new calcium antagonist nisoldipine also increased significantly plasma levels of digoxin (Belz et al., 1983; Kirch et al., 1984 Kirch et al., , 1986a Pedersen et al., 1983) . The rise of the digoxin plasma concentrations with concomitant therapy with calcium channel blockers has been speculated to be due to a reduction of renal excretion of digoxin caused by these drugs (Belz et al., 1983; Pedersen et al., 1981 ). According to data described by Belz et al. (1983) for nifedipine, verapamil and gallopamil with digoxin treatment, the systolic time intervals in the present study were altered by nisoldipine co-administration, too. Eight hours following the last concurrent ingestion of digoxin and nisoldipine, pre-ejection period (PEP) and the ratio of PEP/LVET were significantly shortened compared with the digoxin/placebo values.
Such a spectrum of the behaviour of systolic time intervals is indicative for an afterload reduction, accompanied by some increase in contractility (Belz et al., 1982; Stern et al., 1984) . Therefore these changes seem to be mainly due to the calcium antagonist itself, accompanied by some effect of the increasing plasma digoxin concentration. Similar effects of nisoldipine on systolic time intervals have been described by Debbas et al. (1984) . Other afterload-reducing factors like various diseases or concomitant therapy do not appear to be responsible for the alterations in systolic time intervals seen in the present investigation (see Table 1 ). Remarkable appears to be the fact that in our investigation 3 h after concurrent administration of the calcium antagonist and digoxin the influence of nisoldipine on systolic time intervals could not be detected, whereas it was seen 8 h afterwards. This observation has to be clarified by further investigations about the effect of nisoldipine combined with digoxin on systolic time intervals.
In conclusion data found in our study indicate a significant interaction between nisoldipine and digoxin on a pharmacokinetic basis. The changes in systolic time intervals observed in the present investigation are not necessarily related to the altered plasma digoxin levels, but may be simply a consequence of the addition of the calcium antagonist to the therapy. No adverse effects of the higher digoxin levels were seen in the present study, but in some patients this effect of nisoldipine on digoxin plasma concentrations might be of clinical relevance.
